Onconova Therapeutics Stock Price

-0.05 (-1.36%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Onconova Therapeutics Inc ONTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -1.36% 3.63 06:08:01
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
3.64 3.80 0.16 - -
Trades Volume Avg Volume 52 Week Range
8 310 - 2.40 - 19.30
Last Trade Time Type Quantity Stock Price Currency
05:11:43 formt 207 $ 3.63 USD


Draw Mode:

Onconova Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 57.28M 15.78M 15.71M $ 231.00k $ - -1.95 -3.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 8.40%

more financials information »

Onconova Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.583.913.52983.70482,0520.051.4%
1 Month4.906.76993.475.695,536,619-1.27-25.92%
3 Months5.1326.76993.475.642,034,419-1.50-29.27%
6 Months6.0011.003.478.246,016,851-2.37-39.5%
1 Year2.89819.302.409.5219,726,2010.73225.26%
3 Years61.0062.501.0277.5011,867,660-57.37-94.05%
5 Years384.00582.001.02711.127,373,523-380.37-99.05%

Onconova Therapeutics Description

Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Your Recent History
Onconova T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211018 10:56:55